Neoplasms Clinical Trials
A listing of Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 187 clinical trials
A Phase I/II trial of olaparib palbociclib and fulvestrant in patients with BRCA mutation-associated hormone receptor-positive human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer
The main purpose of this research study is to learn whether the investigational combination of olaparib, palbociclib, and fulvestrant is safe in patients with estrogen receptor-positive (ER+) and/or progesterone receptor-positive (PR+) breast cancer and BRCA1 or BRCA2 mutations.
PHASE I TRIAL OF AUTOLOGOUS T CELLS ENGINEERED TO EXPRESS NY-ESO-1 TCR AND GENE EDITED TO ELIMINATE ENDOGENOUS TCR AND PD-1
This is a Phase 1 first-in-human trial proposed to determine the safety profile and manufacturing feasibility of a single infusion of NYCE T cells on adult patients with myeloma, synovial sarcoma, and myxoid/round cell liposarcoma, and melanoma who have relapsed or refractory tumors expressing NY-ESO-1 antigen.
IMAGING OF PRIMARY OR RECURRENT GYNECOLOGICAL CANCER WITH [18F]FLUORTHANATRACE ([18F]FTT) PET/CT
Women with known or suspected epithelial ovarian, fallopian tube, or primary peritoneal cancer may be eligible for this study. Patients may participate in this study if they are at least 18 years of age. Up to 30 evaluable subjects who have been recommended to start systemic therapy as part of …
Clinical trial of TC-210 T CELLS in Patients with Advanced Mesothelin Expressing Cancer
Your partner is participating in a research study which is looking to determine the safety and efficacy of the drug product, TC-210 T Cells. Your partner has received theTC-210 T Cells. You are being asked to provide information to the Sponsor and your partner’s study doctor, because your partner has …
Identification of neoantigen-specific T cell responses in cancer patients within the Penn Medicine BioBank
You are being asked to participate in this research investigation because you have expressed an interest in participating in a study to better understand how the immune cells of the body recognize and fight cancer.
Pragmatic Clinical Trial Comparing Smoking Cessation Interventions among Underserved Patients who are referred for Lung Cancer Screening
Low-dose computed tomography (LDCT) screening reduces mortality among current and former smokers at high risk for lung cancer, and is widely recommended by national guidelines. LDCT also increases access to care and thus provides an opportunity to deliver smoking cessation interventions to current smokers in conjunction with this screening. As …
Randomized Trial of Stepped Palliative Care versus Early Integrated Palliative Care in Patients with Advanced Lung Cancer
We are inviting you to take part in a research study. Research is a way of gaining new knowledge. A person who participates in a research study is called a “participant.” This research study is evaluating ways to provide palliative care to patients who have recently been diagnosed with lung …
The Association Between CBT-I Dose and Innate Immunity in Insomnia and Fatigue in Prostate Cancer Patients
The research study is being conducted secondary and after your completion of the primary study (Effect of Radiation Therapy on Sleepiness and Activity in Prostate and Breast Cancer Patients). The purpose of the current study is to assess the effectiveness of a behavioral treatment for insomnia (also known as Cognitive …
UPCC 07117: A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination with Paclitaxel in Patients with Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry
Request for collaborative review: WIRB serving as IRB of record.
UPCC 13118: Palbociclib After CDK and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant Palbociclib and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer
To evaluate progression-free survival (PFS) using traditional RECIST critiera with the combination of fulvestrant and palbociclib vs. fulvestrant alone in patients with advanced HR+/HER2- breast cancer that has progressed despite prior CDK4/6 inhibition and endocrine therapy.
